Sign up
Pharma Capital
Why invest in RGS?

Regeneus: Access latest PPT from Proactive's CEO Sessions

John Martin discussed regenerative medicine with investors.
Regeneus: Access latest PPT from Proactive's CEO Sessions
John Martin, chief executive officer, Regeneus

Regeneus (ASX:RGS) chief executive officer, John Martin, joined Proactive's CEO Sessions in Sydney on Wednesday 14th June and Melbourne on Thursday 15th June.

The company provides exposure to the rapid growth global regenerative medicine market, utlising its world-calss stem cell and immuno-oncology technology platforms.

Its technology has been validated by positive pre-clinical and clinical data, and by a collaboration with a leading biopharma manufacturer in Japan.


Register here to be notified of future RGS Company articles
View full RGS profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.